|
|
|
|
||
Value equivalencyBluebird, founded 23 years ago, now has a market cap of $2.75 Billion, and has zero products on the market. Juno, a more recent start up, now has a market cap of $2.75 Billion and has zero products on the market. Both have very close relationship with a major pharma; NVS in the case of Juno and Celgene in the case of Bluebird. Sangamo, if they too would "affiliate" with a major pharma, would, one would think, similarly be worth $2.75 billion. That would put the present Sangamo shares @ $40 per share on the 68 million shares presently outstanding. I have no idea what EL's next major corporate move will be; do any of you ??? MERRY CHRISTMAS TO ALL; AND A HAPPY, HAPPY NEW YEAR TO ALL OF MY FELLOW LONGS. ICKYPICKY |
return to message board, top of board |